Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $8.77, for a total value of $17,540.00. Following the completion of the transaction, the chief executive officer now owns 14,611,662 shares of the company’s stock, valued at $128,144,275.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 13th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.37, for a total value of $16,740.00.
• On Monday, November 11th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $9.09, for a total value of $18,180.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.82, for a total value of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.67, for a total value of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total value of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Trading Down 5.1 %

Shares of Zynex stock opened at $8.13 on Thursday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77. The stock has a 50 day moving average price of $8.22 and a two-hundred day moving average price of $8.92. The stock has a market capitalization of $258.94 million, a PE ratio of 54.20 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. Zynex’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.10 earnings per share. As a group, equities analysts anticipate that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on ZYXI. HC Wainwright raised their target price on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada reduced their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its position in shares of Zynex by 68.7% during the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after buying an additional 77,300 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Zynex by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock valued at $14,684,000 after buying an additional 6,097 shares during the last quarter. Millennium Management LLC boosted its position in shares of Zynex by 66.5% during the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after buying an additional 118,615 shares during the last quarter. Quest Partners LLC boosted its position in shares of Zynex by 646.7% during the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after buying an additional 11,195 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new stake in Zynex during the first quarter worth $137,000. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.